Hepion Pharmaceuticals, Inc. - Investor Summit Group

Hepion Pharmaceuticals, Inc.

Ticker

HEPA

Website

Sector

Biotech

Tearsheet

Why Invest

Hepion (Nasdaq:HEPA) is a mid-stage biopharmaceutical company developing a novel compound, rencofilstat, for the treatment of Non-Alcoholic Steatohepatitis (NASH) and Hepatocellular Carcinoma (HCC). Rencofilstat is the only drug candidate in development for both indications that belongs to a novel class, called cyclophilin inhibitors. Harnessing bioinformatics and artificial intelligence to optimize clinical development of rencofilstat. Hepion’s core scientific team has >100 years’ experience in cyclophilin drug development and has already discovered and developed a commercially successful drug for kidney disease (lupus nephritis.)